enGene Therapeutics (ENGN) director receives 31,000 stock options at $1.75 strike

Rhea-AI Filing Summary

enGene Therapeutics Inc. director Richard M. Glickman received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. Following this grant, he holds 31,000 options directly.

The option award vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Glickman Richard M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 31,000 options Exercise price: $1.75 per share Expiration date: June 16, 2036 +2 more

5 metrics

Options granted 31,000 options Stock Option (Right to Buy) grant to director

Exercise price $1.75 per share Strike price for 31,000 option shares

Expiration date June 16, 2036 Option term end date

Holdings after grant 31,000 options Total derivative holdings following transaction

Vesting trigger Earlier of June 9, 2027 anniversary or 2027 meeting Full vesting condition from footnote

Key Terms

Stock Option (Right to Buy), exercise price, vesting commencement date, annual meeting of shareholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.7500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting commencement date financial

"the first anniversary of the vesting commencement date, which was June 9, 2026"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

annual meeting of shareholders financial

"the registrant's 2027 annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/17/2026 - 05:42 PM Accepted by SEC EDGAR 06/17/2026 - 05:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glickman Richard M

(Last) (First) (Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT H4R 2P1

(City) (State) (Zip)

QUEBEC, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
enGene Therapeutics Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.75	06/16/2026		A		31,000		(1)	06/16/2036	Common Shares	31,000	$0	31,000	D

Explanation of Responses:

1. This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.

	/s/ Alex J. Nichols, as attorney-in-fact for the Reporting Person	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did enGene Therapeutics (ENGN) insider Richard Glickman report on this Form 4?

Richard M. Glickman reported receiving a grant of stock options for 31,000 enGene Therapeutics common shares. These options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a preset exercise price.

How many enGene Therapeutics (ENGN) options did Richard Glickman receive and at what price?

He received stock options covering 31,000 common shares of enGene Therapeutics with an exercise price of $1.75 per share. This means he can buy those shares at $1.75 once the options vest and before they expire.

When do Richard Glickman’s enGene Therapeutics (ENGN) options vest?

The options vest fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or enGene Therapeutics’ 2027 annual meeting of shareholders. Full vesting must occur before he can exercise all granted options.

When do Richard Glickman’s enGene Therapeutics (ENGN) options expire?

These stock options expire on June 16, 2036. After that date, any unexercised options become worthless, so the holder must exercise vested options before expiration to acquire the underlying enGene Therapeutics common shares at the exercise price.

Is this enGene Therapeutics (ENGN) Form 4 a stock purchase or sale?

It is not a market purchase or sale. The Form 4 shows a grant of stock options to Richard Glickman as compensation. No open-market buying or selling of enGene Therapeutics common shares is reported in this transaction data.

How many enGene Therapeutics (ENGN) options does Richard Glickman hold after this grant?

After this grant, Richard Glickman holds 31,000 stock options directly. Each option is linked to one enGene Therapeutics common share, giving him the right to purchase up to 31,000 shares at the specified exercise price if fully vested and exercised.